Navigation Links
Candela Receives Registration Approval to Market Its Best-in-Class GentleMax and Alex TriVantage Lasers in China
Date:2/10/2010

WAYLAND, Mass., Feb. 10 /PRNewswire/ -- Candela Corporation, a Syneron company (Nasdaq: ELOS), announced today that the SFDA (State Food and Drug Administration) of China has approved the Alex TriVantage® multi-wavelength, Q-switched laser system and the GentleMax® multiple wavelength workstation for sale throughout the People's Republic of China, including Hong Kong. The receipt of the SFDA Certificates will allow Candela to begin the sales process and launch official marketing programs for these products, creating a host of new market opportunities.

The unique Q-switched Laser-Pumped-Laser (LPL) technology of the Alex TriVantage laser provides 755-nm, 532-nm and 1064-nm output wavelengths, making Alex TriVantage extremely versatile. The addition of a long-pulse mode at 755 nm offers advanced treatments for a wider variety of pigmented lesions (many unique to Asian skin) without long-term side effects. Beyond the treatment of benign pigmented lesions and the removal of multi-color tattoo inks, Alex TriVantage enhances the results of many skin rejuvenation treatments, making it an ideal system for optimizing fractional and other rejuvenation treatment results. 

By integrating two of aesthetic laser medicine's leading devices, the GentleLASE and GentleYAG, into a configurable, upgradeable workstation, the GentleMax has made treatment for a wider range of patient concerns more readily available. The GentleMax laser system features both 755-nm and 1064-nm wavelengths and may be used to provide permanent hair reduction on all skin types and tanned skin as well as the treatment of vascular and pigmented lesions, wrinkle reduction and skin tightening. With GentleMax, it is now possible for one device to do the work of two or more.

"The Alex TriVantage is our first Q-switched alexandrite laser to be approved in China," said Syneron Chief Executive Officer Louis P. Scafuri. "With its unique Laser-Pumped-Laser (LPL) technology and GentleMax's multiple wavelengths and uses, a greater number of physicians will be able to offer a wider variety of services for conditions with fewer devices. Moreover, this approval enables us to offer a more complete range of highly effective aesthetic solutions in the world's largest market."   

For more information on the GentleMax and Alex TriVantage lasers, visit www.candelalaser.com

About Candela

Candela is a wholly-owned subsidiary of Syneron Medical Ltd. (NASDAQ: ELOS), the global leader of aesthetic devices offering the industry's most comprehensive product portfolio and worldwide distribution footprint. The Candela brand supports Syneron's line of aesthetic therapies for the face and body with four decades of industry-leading scientific expertise and innovative aesthetic laser technologies. Syneron distributes and supports its products in 86 countries with offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong. Additional information can be found at www.syneron.com.

SOURCE Candela Corporation

RELATED LINKS
http://www.candelalaser.com
http://www.syneron.com

'/>"/>

SOURCE Candela Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
Breaking Medicine News(10 mins):